P48.05 Is Relapse-Free Survival at 2-Years an Appropriate Surrogate for Overall Survival at 5-Years in EGFR-mutated Resected NSCLC?
Miguel García-Pardo(Hospital Universitario Ramón y Cajal), G. Liu, Khaleeq Khan(Princess Margaret Cancer Centre), Reenika Aggarwal, M. Catherine Brown(University Health Network), Katrina Hueniken(Centre for Addiction and Mental Health), Adrian G. Sacher(Princess Margaret Cancer Centre), Sussane Schmid, D. Patel(Princess Margaret Cancer Centre), Luna Jia Zhan(University Health Network), S.P. Chan, Aline Fusco Fares(Hospital de Base), Frances A. Shepherd(University Health Network), E. Smith, Karmugi Balaratnam(Princess Margaret Cancer Centre), Penelope A. Bradbury(University Health Network), Natasha B. Leighl(Princess Margaret Cancer Centre)
Cited by 3
Related Papers
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer
|New England Journal of Medicine|2016|3.3k
Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy
|Journal of Clinical Oncology|2004|2.4k
Early palliative care for patients with advanced cancer: a cluster-randomised controlled trial
|The Lancet|2014|1.8k
Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation
|New England Journal of Medicine|2021|1.8k